Healthcare / Drug Manufacturers - Specialty & GenericNSE
$6063.00
-191.50 (-3.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.1B · quality 79.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$100.6B
P/E
30.8x
↑EV/EBITDA
20.9x
↑ROE
62.3%
↑Gross Margin
74.1%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2026 · 4 años de histórico normalizado
Revenue CAGR
+6.6%
FCF CAGR
+25.1%
FCF margin
22.9%
FCF / Net income
0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.08B · net income $3.27B · FCF $3.22B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.08B | $14.08B | $11.29B | $12.06B | $10.92B |
| Net Income | $3.27B | $3.27B | $2.01B | $2.29B | $1.93B |
| EBITDA | $4.74B | $4.74B | $3.01B | $3.43B | $2.81B |
| EPS | — | — | 121.00 | 138.00 | 116.00 |
| Gross Margin | 74.1% | 74.1% | 68.2% | 67.5% | 66.4% |
| Operating Margin | 30.8% | 30.8% | 24.7% | 24.5% | 22.7% |
| Net Margin | 23.2% | 23.2% | 17.8% | 19.0% | 17.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 |
| Current Ratio | 2.18 | 2.18 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $3.22B | $3.22B | $2.07B | $1.94B | $1.32B |
| Returns | |||||
| ROE | 62.3% | 62.3% | 37.3% | 30.6% | 31.2% |
| Valuation | |||||
| P/E | 30.80 | 30.80 | 42.77 | 37.35 | 36.83 |
| EV/EBITDA | 20.88 | 20.88 | 27.74 | 23.71 | 24.13 |
| P/B | 19.19 | 19.19 | 15.96 | 11.39 | 11.50 |
| Growth & Yield | |||||
| Revenue Growth | 24.7% | 24.7% | -6.3% | 10.4% | — |
| EPS Growth | — | — | -12.3% | 19.0% | — |
| Dividend Yield | 2.6% | 2.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.7%
Start / end P/E
n/dx → n/dx
EPS bridge
121.00 → n/d
Residual
+12.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.